New therapeutic target expands options for multiple myeloma. In a phase 1 clinical trial, treatment with the investigational bispecific antibody cevostamab reduced cancer in more than 40% of patients with multiple myeloma, many of whom had already undergone multiple other cancer treatments, and produced a median duration of response of 11.2 months before the cancer progressed.
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: In a phase 1 clinical trial, treatment with the investigational bispecific antibody cevostamab reduced cancer in more than 40% of patients with multiple myeloma, many of whom had already undergone multiple other cancer treatments, and produced a median duration of response of 11.2 months before the cancer progressed.
- Ponto de atenção: therapeutic.
- Ponto de atenção: target.
- Ponto de atenção: expands.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.
